You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
凱萊英(002821.SZ):與法爾瑪製藥簽署核酸藥物API產能建設項目委託代建與運營合同
格隆匯 04-22 22:09

格隆匯 4 月 22日丨凱萊英(002821.SZ)公佈,公司全資子公司凱萊英生命科學技術(天津)有限公司(凱萊英生命科學)天津法爾瑪製藥有限公司(法爾瑪製藥)2021422簽署《關於核酸藥物API產能建設項目委託代建與運營合同》,接受其委託,就“核酸藥物API產能建設項目”代為建設和運營中試&產業化規模的核酸藥物API GMP廠房等設,對項目建設實施進行全過程管理,並在該項目完成建設後對其進行運營。

鑑於天津海河凱萊英生物醫藥產業創新投資基金(有限合夥)(“海河凱萊英基金”)已2021422日與法爾瑪製藥簽署《增資協議》,海河凱萊英基金將6500萬人民幣對法爾瑪製藥增資,完成後將持有法爾瑪製藥95.20%股權,海河凱萊英基金系公司關聯方根據《深圳證券交易所股票上市規則》相規定公司本着審慎和實質重於形式的原則,法爾瑪製藥與公司構成關聯關係該代建事項在公司董事會審議權限內,無需提交公司股東大會審議。待後期該目建設驗收後代為運營管理階段時,公司將根據代運營部分的涉及的權利與義務所履行相應的審議程序和披露義務。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account